↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Thermo Fisher Scientific$TMO · filed: grew revenue 3.9% in FY2025 to $44.6BSound shipTrillion Score 500Fall Risk LowNext year $39.7B–$48.4B sealedCheck ▾Close ▴
What Thermo Fisher Scientific filed
Grew revenue 3.9% in FY2025 to $44.6 billion, operating margin 17.4% against a 9.4% median for measuring & controlling devices, equity 48.4% of assets, and dividend per share up 8 years running. Every figure links to the filing it came from on Thermo Fisher Scientific’s card. Sound ship: one warning sign. Trillion Score 500, #31 of 59 in its field; Fall Risk Low (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $39.7B and $48.4B, an 80% range sealed on 26 Sept 2026 · receipt #9ba1c4 · graded in public by the revenue in Thermo Fisher Scientific’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
A **$1 billion** clean exit that funds Thermo Fisher's margin expansion while handing Astorg a platform for roll-up plays in legacy diagnostics.
$400 million
in annual revenue with mid-teens EBITDA margins—solid but below…
25 to 30 percent
margins Thermo Fisher commands in its core mass spectrometry…
$44 billion
in annual revenue across four segments
1,200
people across manufacturing sites in France
Thermo Fisher Scientific completed the sale of its microbiology business to Paris-based private equity firm Astorg for $1 billion cash, closing a transaction first floated in March 2024. The unit, which produces culture media, Petri dishes, and manual microbiology instruments, generated approximately $400 million in annual revenue with mid-teens EBITDA margins—solid but below the 25 to 30 percent margins Thermo Fisher commands in its core mass spectrometry and genomics divisions.
The deal removes a non-core asset from a company that derives $44 billion in annual revenue across four segments. Thermo Fisher has spent the past eighteen months pruning lower-margin diagnostics and research consumables while doubling down on pharma services and biopharma production. The microbiology unit employed roughly 1,200 people across manufacturing sites in France, the UK, and New Zealand—geographies Astorg knows well. Astorg's healthcare team previously carved out and scaled similar legacy diagnostics businesses, including bioMérieux's industrial hygiene division in 2019.
The timing reflects broader pressure in life sciences. Channel inventories remain elevated after the COVID boom, NIH grant funding has flattened, and Chinese competition in reagents and plasticware has compressed pricing by 12 to 18 percent over two years. Thermo Fisher's stock trades at 18 times forward earnings, down from a pandemic peak of 26 times, and management has signaled that capital allocation will prioritize share buybacks and tuck-in M&A in higher-margin automation and digital pathology. Selling the microbiology business frees $1 billion for that playbook while eliminating a unit that would have required $150 million in capital expenditures over the next three years to stay competitive with automated systems from BD and bioMérieux.
Astorg's entry is clean execution. The firm raised a €4.1 billion Fund VI in late 2023 and has deployed roughly €1.8 billion into twelve healthcare and tech deals since. Microbiology diagnostics—especially culture-based testing—remains a $6 billion global market with 4 to 5 percent organic growth, driven by hospital infection control mandates and food safety regulations. The business is a platform candidate: Astorg can bolt on adjacencies in rapid diagnostics or point-of-care testing, then exit to a strategic acquirer or secondary PE buyer in four to six years. The firm's prior exits in diagnostics have averaged 2.8 times money-on-money returns.
Allocators should track Thermo Fisher's Q1 2025 earnings call in late April for clarity on buyback acceleration and whether the company pursues another divestiture in its transplant diagnostics segment, which has drawn interest from Permira and KKR. Astorg will likely announce a CEO hire for the standalone microbiology entity within 90 days and file integration plans with European works councils by June. Watch for follow-on acquisitions by Astorg in adjacent diagnostics verticals—culture media companies in the $200 to $400 million revenue range in Germany and the U.S. remain underowned and ripe for carve-outs.
Thermo Fisher's 2025 free cash flow guidance of $9 billion now carries $1 billion less reinvestment drag, and Astorg has €2.3 billion of dry powder left to deploy before Fund VI's investment period closes in 2027.
Branded by POPS4 · proof in 60 seconds
For the principal
Track whether Thermo Fisher divests transplant diagnostics next; margin compression in consumables argues for more portfolio pruning through mid-2025.
For the operator
Astorg will hunt bolt-ons in culture media and rapid diagnostics; watch carve-out opportunities in German and U.S. mid-market diagnostics over six months.
For the house
Short-term neutral on TMO; reallocate watchlist capacity to BD and bioMérieux as microbiology consolidation accelerates under PE ownership through 2026.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
